FindTrial
Sign In

Phase II clinical study in patients with Parkinson's disease taking L-DOPA

A randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPA

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221835
Enrollment
Unknown
Registered
2012-06-21
Start date
2012-06-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : HP-3000(ropinirole hydrochloride patch) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administrat

Sponsors

Hisamitsu Pharmaceutical Co.,Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with Parkinson's disease in stages 2 to 4 on the modified Hoehn & Yahr scale

Exclusion criteria

Exclusion criteria: - Patients with history of hypersensitivity to ropinirole - Patients with clinically significant renal impairment or hepatic dysfunction - Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product

Design outcomes

Primary

MeasureTime frame
Efficacy—

Secondary

MeasureTime frame
Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026